Open An Account

Ipca Laboratories Ltd.

BSE : 124494 NSE : IPCALAB ISIN : INE571A01038 Industry : Pharmaceuticals & Drugs
1,149.70
B S Sip
Change: 16.75 (1.48 %)
As on 01-Dec-2023 12:00 AM
Advance Chart
Prev.Close 1,132.95
Open 1,133.00
Day's High 1,153.00
Day's Low 1,123.95
Mkt.Cap ( Cr.) 29,168.35
Face Value 1.00
PE Ratio 58.38
PB Ratio 3.50

52 Week High Low

Low: 669.80
High: 1,153.00
LTP:1,149.70

Lifetime High Low

Low: 2.75
High: 1,383.10
LTP:1,149.70

Ipca Laboratories Ltd.

BSE : 124494 NSE : IPCALAB ISIN : INE571A01038 Industry : Pharmaceuticals & Drugs
1,148.50
B S Sip
Change: 15.75 (1.39 %)
As on 01-Dec-2023 12:00 AM
Advance Chart
Prev.Close 1,132.75
Open 1,132.75
Day High 1,152.55
Day Low 1,125.00
Mkt.Cap ( Cr. ) 29,137.90
Face Value 1.00
P/E Ratio 58.38
PB Ratio 3.50

52 Week High Low

Low:670.00
High:1,152.55
LTP:1,148.50

Lifetime High Low

Low:2.83
High:1,383.55
LTP:1,148.50
Advance Chart

P/E Ratio

52 W L(14.96)
52 W H(40.26)

P/E Ratio

52 W L(14.96)
52 W H(40.26)
Had I Invested a sum of 1,00,000 on the same day 5 years ago,the money would have become 285817.28 ( a of 23.37 p.a.)

Key Levels and Moving Averages

Take a quick peak at the technical support and resistance levels of the stock price along with various moving average numbers automatically calculated for you

Key Levels

Support Level 1 1,120.17
Support Level 2 1,107.38
Resistance Level 1 1,141.87
Resistance Level 2 1,150.78

Moving Average

20 Days 1,056.02
50 Days 989.37
100 Days 924.64
200 Days 846.62

Peer Companies

Compare the performance of a stock with the other stocks from the same sector

Jubilant Pharmova Ltd. 453.05 Change: 23.60 (5.50%)
PE : 0.00
1Y Return: 15.71%

B S
Vineet Laboratories Ltd. 70.60 Change: 2.75 (4.05%)
PE : 10.18
1Y Return: 23.75%

B S
Orchid Pharma Ltd. 589.50 Change: 20.85 (3.67%)
PE : 30.08
1Y Return: 48.36%

B S
Aarti Pharmalabs Ltd. 425.50 Change: 13.85 (3.36%)
PE : 19.28
1Y Return: 0.00%

B S
View More

Key Ratios

A quick glance at the key aspects of the company's financial picture such as liquidity, profitability and earnings strength

FY 2023FY 2022FY 2021FY 2020FY 2019
EBDITA Margin (%)17.6423.8030.7222.5020.65
PBT Margin (%)12.9119.7526.8517.9715.34
PAT Margin (%)8.7015.8222.2014.9412.52
ROCE (%)11.7719.3430.5420.8416.76
ROE (%)8.9116.8227.1019.1815.60

Profit & Loss

Stay on top of the company’s Quarterly/Half Yearly/Yearly P&L statement to take an in-depth look at a company’s financial performance

FY 2023FY 2022FY 2021FY 2020FY 2019
Total Income ( Cr.)5,912.065,514.185,242.714,421.983,677.23
Gross Profit ( Cr.)979.121,283.761,567.68963.66729.27
Profit Before Tax ( Cr.)750.491,074.111,379.96784.97557.39
Tax ( Cr.)244.79213.74239.19132.51102.48
Profit After Tax ( Cr.)505.70860.371,140.77652.46454.91

Shareholding Pattern & Management

NAME DESIGNATION
Harish P Kamath Corporate Counsel & Company Secretary
Premchand Godha Chairman
Ajit Kumar Jain Managing Director
Pranay Godha Managing Director
Prashant Godha Executive Director
Anand T Kusre Non Executive Independent Director
Manisha Premnath Non Executive Independent Director
Kamal Kishore Seth Non Executive Independent Director
Narendra Mairpady Non Executive Independent Director

Corporate Action

Stay abreast of the latest bonus, dividend and other corporate action news of the company to take informed investment decisions

No Data Available

MF Holding

Take a peek into the mutual funds, which hold the stock in their portfolio as of the last reported quarter

Scheme Name AUM% Value(Rs. Cr.) Holding Date
HDFC Mid-Cap Opportunities Fund - Growth Know More 2.77 1,326.74 31-Oct-2023
Kotak Emerging Equity Fund - Growth Know More 2.05 689.91 31-Oct-2023
DSP Midcap Fund - Regular Plan - Growth Know More 3.88 561.21 31-Oct-2023
Parag Parikh Flexi Cap Fund - Regular Plan - Growth Know More 0.79 348.43 31-Oct-2023
DSP Small Cap Fund - Regular Plan - Growth Know More 2.68 317.71 31-Oct-2023
View More

News

Ipca Laboratories gains despite reporting 6% fall in Q2 consolidated net profit
Type: MOVERS TODAY
Date: 13-Nov-2023 03:16 PM
Total consolidated income of the company increased by 26.59% at Rs 2,072.51 crore for Q2FY24
Ipca Laboratories reports 6% fall in Q2 consolidated net profit
Type: NEWS
Date: 13-Nov-2023 03:12 PM
Total consolidated income of the company increased by 26.59% at Rs 2,072.51 crore for Q2FY24
Ipca Laboratories reports Profit after tax of Rs 1621.30 Mln, in the September 2023 quarter
Type: CORPORATE RESULT
Date: 10-Nov-2023 01:39 PM
--
Ipca Laboratories gets VAI classification for Indore facility
Type: NEWS
Date: 31-Oct-2023 11:52 AM
USFDA inspected the company’s said manufacturing facility from June 15, 2023 to June 23, 2023
Ipca Laboratories zooms despite getting VAI classification for Madhya Pradesh facility
Type: MOVERS TODAY
Date: 23-Oct-2023 11:50 AM
USFDA inspected the company’s said manufacturing facility from June 05, 2023 to June 13, 2023
Ipca Laboratories gets VAI classification for Madhya Pradesh facility
Type: NEWS
Date: 23-Oct-2023 11:40 AM
USFDA inspected the company’s said manufacturing facility from June 05, 2023 to June 13, 2023
View More